|
Vitruvia Medical AG / Key word(s): Half Year Results/Half Year Report Vitruvia Medical AG: Consolidated interim results as per June 30th,2023 29-Sep-2023 / 12:15 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Consolidated interim results as per June 30th,2023 Vitruvia Medical AG achieves results as expected in the first half of 2023. The Board of Directors confirms the guidance for the full year. Vitruvia Medical AG is on target in the first six months of 2023. The company generated consolidated revenues of approximately EUR 855,000.00 in the first half of 2023, with earnings before interest, taxes, depreciation and amortization of EUR -176,884.00. Based on the results for the first half of 2023, which were as expected, the management confirms the outlook for the current full year. For this period, the Board of Directors expects consolidated revenues of approximately EUR 1.8 million. On a consolidated basis, Vitruvia Medical AG anticipates a further improvement in earnings compared to the previous year, which will, however, still be in negative territory. End of Inside Information 29-Sep-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
CDC Advisors Back Updated COVID, Flu Vaccines for the Fall
The CDC’s Advisory Committee on Immunization Practices (ACIP) endorsed new COVID-19 and influenza vaccines for the 2024-2025 respiratory virus season on Thursday. In a unanimous
June 29, 2024